Guidelines on the laboratory diagnosis of congenital bleeding disorders in Pakistan

Journal of the Pakistan Medical Association

Volumn 62, Issue 5, 2012, Pages 477-486

  Borhany, Munira ^a   Shamsi, Tahir ^a   Moiz, Bushra ^a   Hasan, Khalid ^a   Hashmi, Khalid Zafar ^a   Ayyub, Muhammad ^a   Ali, Nadir ^a   Amanat, Nisar Ahmed Samina ^a   Zafar, Tahira ^a  

^a NONE

Author keywords

Congenital bleeding disorders; Haemophilia A; Inhibitors; Pakistan; Platelet functional disorder; Von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 INHIBITOR; BLOOD CLOTTING INHIBITOR; FIBRINOGEN; PROTHROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ANAMNESIS; BLEEDING DISORDER; BLEEDING TIME; BLOOD CELL COUNT; BLOOD GROUP ABO SYSTEM; DNA SEQUENCE; HEMOPHILIA A; HEMOPHILIA B; HUMAN; INFORMATION RETRIEVAL; LABORATORY DIAGNOSIS; PAKISTAN; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PROTHROMBIN TIME; REVIEW; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE DISORDER; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS; BLOOD COAGULATION TESTS; HUMANS; PAKISTAN;

EID: 84860183180     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Laffan MA, Lee CA. Inherited bleeding disorders. In Hoffbrand AV, Catovsky D, Tuddenham EGD. Postgraduate Haematology. 5th ed. USA: Blackwell Publishing Inc; 2005; 825-41.
2. Hoyer LW. Haemophilia A. N Engl J Med 1994; 330: 38-47.
3. Mannucci PM, Tuddenham EG. The haemophilias-from royal genes to genes therapy. N Engl J Med 2001; 344: 1773-9.
4. Sadler JE, Mannucci PM, Berntorp E, Bochkoy N, Boulyienkov Y, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
5. Srivastava A, Rodeghiero F. Epidemiology of von Willebrand disease in developing countries. Semin Thromb Hemost 2005; 31: 569-76.
6. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14: 171-232.
7. Gupta M, Bhattacharyuya M, Choudhry VP, Saxena R. Spectrum of inherited bleeding disorders in Indians. Clin Appl Thromb Hemost 2005; 11: 325-30.
8. Karimi M, Yarmohammadi H, Ardeshiri RM, Yarmohammadi H. Inherited coagulation disorders in southern Iran. Haemophilia 2002; 8: 740-4.
9. Ahmed F, Kannan M, Ranjan R, Bajaj J, Choudhary VP, Saxena J. Inherited platelet function disorders versus other inherited disorders: an Indian overview. Thromb Res 2008; 121: 835-41.
10. Nurden AT, Nurden P. Inherited defects of platelet function. Rev Clin Exp Hematol 2001; 5: 314-34.
11. Nurden AT. Qualitative disorders of platelets and megakaryocytes. J Thromb Haemost 2005; 3: 1773-82.
12. Cattaneo M. Inherited platelet abnormalities. Thromb Res 2005; 115: 10-3.
13. Sramek A, Eikenboom JC, Briet E, Vandenbroucke JP, Rosendaal FR. Usefulness of patient interview in bleeding disorders. Arch Intern Med 1995; 155: 1409-15.
14. Wahlberg T, Blomback M, Hall P, Axelsson G. Application of indicators, predictors and diagnostic indices in coagulation disorders: II. Evaluation of laboratory variables with continuous test results. Methods Inf Med 1980; 19: 201-5.
15. Laffan MA, Manning RA. Investigation of haemostasis. In Dacie JV, Lewis SM. Lewis practical haematology.9th Ed Churchill Livingstone, 2001; 339-90.
16. Kitchen S, Makris M. Laboratory tests of hemostasis. In Practical Hemostasis and Thrombosis. O'Shaughnessy, Makris M, Lillicrap D. Oxford, UK: Blackwell Publishing Ltd 2005; 8-37.
17. Visudhiphan S. Laboratory manual of hemostasis. By Ruen Kaew Bangkok, Thailand: 1992.
18. Kitchen S, McCraw A. Diagnosis of Haemophilia and other Bleeding disorders, A laboratory manual. The World Federation of Hemophilia Laboratory Sciences Committee 2000; 05-105.
19. Mannucci PM, Canciani MT, Mari D, Meucci P. The sensitivity of partial thromboplastin and prothrombin time reagents in the demonstration of the lupus- like anticoagulant. Scand J Haematol 1979; 22: 423-32.
20. No author listed. Guidelines on platelet function testing. The British Society for Haematology BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol 1988; 41: 1322-30.
21. Bolton-Maggs PH, Chalmers EA, Collins PW, Harrison P, Kitchen S, Liesner RJ, et al. A review of inherited platelet disorders with guidelines for their management on behalf of the UKHCDO. Br J Haematol 2006; 135: 603-33.
22. Kasper CK. Diagnosis and Management of inhibitors to factors VIII and IX. World federation of Haemophilia 2004; 34: 1-11.
23. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia. Haemophilia 2006; 12: 52-60.
24. Hay CR and Lee CA. Inhibitors. In: Inhibitors in patients with Haemophilia (ed by E.C. Roiguez-Merchan & C.A. Lee). Berlin: Blackwell; 2002.
25. Warrier I. Management of haemophilia B patients with inhibitors and anaphylaxis. Haemophilia 1998; 4: 574-6.
26. Hay CR, Brown S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organization. Br J Haematol 2006; 133: 591-605.
27. No author listed. Letter: A more uniform measurement of FVIII inhibitor. Thromb Diath Haemorrh 1975; 34: 869-72.
28. Verbruggen B, Novakova I, Wessels H, Boezeman J, Van den Berg M, Mauser Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII: C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
29. Lee M, Morfini M, Schulman S. The design and analysis of pharmacokinetic studies of coagulation factors. Factor VIII/IX SSC-ISTH 2001 recommendations. (Online) Available from URL: http:/www.med.unc.edu/isth/fviiipharmaco.htm.
30. Bjorkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clinical Pharmacokinet 2001; 40: 815-32.
31. Morfini M. Pharmacokinetics of factor VIII and IX. Haemophilia 2003; 9 (Suppl 1): 94-100.
32. Dilley A, Drews C, Miller C, Austin H, Ramaswamy D, Lurye D, et al. Von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet Gynecol 2001; 97: 630-6.
33. Woo YL, White B, Corbally R, Byrne M, O'Connell N, O'Shea E, et al. Von Willebrand's disease: an important cause of dysfunctional uterine bleeding. Blood Coagul Fibrinolysis 2002; 13: 89-93.
34. Lillicrap D, Nair SC, Srivastava A, Rodeghiero F, Pabinger I, Federici B. Laboratory issues in bleeding disorders. Haemophilia 2006; 12 Suppl 3: 68-75.
35. Sadler JE, Rodeghiero F; ISTH SSC Subcommittee on von Willebrand Factor. Provisional criteria for the diagnosis of VWD type 1. J Thromb Haemost 2005; 3: 775-7.
36. Srivastava A. von Willebrand disease in the developing world. Semin Hematol 2005; 42: 36-41.